Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696279 | 0.85 | AGTR2 (0.35) | — | |
| SCHEMBL5185468 | 0.76 | TACR1 (0.39) | KMT2AMMP2ANPEPALDH1A1 | |
| SCHEMBL5185521 | 0.74 | HHAT (0.36) | KMT2AHHATMMP2 | |
| SCHEMBL5186929 | 0.74 | BUB1 (0.32) | KMT2AMMP2ANPEPALDH1A1MAPT | |
| SCHEMBL5186998 | 0.70 | PLK1 (0.33) | ALDH1A1 | |
| SCHEMBL4138455 | 0.69 | KMT2A (0.42) | KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9834873 | 0.67 | KMT2A (0.64) | KMT2AHTR2CALDH1A1MAPT | |
| SCHEMBL5187106 | 0.64 | KMT2A (0.35) | KMT2AHHAT | |
| SCHEMBL5187101 | 0.64 | KMT2A (0.35) | KMT2AHHAT | |
| SCHEMBL1425950 | 0.64 | HTR2C (0.38) | KMT2AHTR2CSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | KMT2A 2499/4885HTR2C 4105/4885SMN1; SMN2 4403/4885 |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | KMT2A 3643/4885HTR2C 4763/4885SMN1; SMN2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.